PBYI Puma Biotechnology Inc

-0.75  -1%
Previous Close 124.30
Open 124.40
Price To book 38.25
Market Cap 4596751509
Shares 37,205,597
Volume 383,814
Short Ratio 4.44
Av. Daily Volume 774,776

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Note this trial is conducted by competitor Roche (RHHBY), NOT by Puma. Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Roche (RHHBY) - Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Phase 2 data released at ASCO June 3, 2017.
HER2-positive metastatic breast cancer patients with brain metastases
Phase 3 planned
Neratinib plus temsirolimus
Fourth line HER2-positive metastatic breast cancer
Phase 2 biomarker data released December 7, 2016.
PB272 (NSABP FB-7)
Neoadjuvant treatment for patients with HER2-positive breast cancer
Phase 2 preliminary data released December 8, 2016 with further data presented April 2, 2017.
Neratinib SUMMIT
HER2 non-amplified breast cancer that has a HER2 mutation
Phase 2 additional data released December 8 2016 and April 4, 2017. Noted high rates of diarrhea. Additional data due 4Q 2017.
Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
Extended adjuvant treatment of early stage HER2-positive breast cancer
Phase 3 data due 1H 2018.
Third-line HER2-positive metastatic breast cancer
Phase 2 completed.
Neratinib - NEfERTT trial
HER2-positive breast cancer first line
Approval announced July 17, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.
Neratinib (NERLYNX)
Extended adjuvant HER2-positive early stage breast cancer

Latest News

  1. Bitcoin vs. Biotech: Which Is the Smarter Investment?
  2. Lifshitz & Miller LLP Announces Investigation of Equifax Inc., Intercept Pharmaceuticals, Inc., Inventure Foods, Inc., Puma Biotechnology, Inc., Tintri, Inc., Twenty-First Century Fox, Inc. and Ubiquiti Networks, Inc.
  3. Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference
  4. Before You Buy Puma Biotechnology Inc’s (PBYI), You Should Consider This
  5. 4 Biotech Stocks for the Long-Term
  6. Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress
  7. Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference
  8. Puma Biotechnology Announces Publication of Abstracts for ESMO 2017
  9. Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  10. PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. – PBYI
  11. Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus
  12. Puma Biotech reports 2Q loss
  13. Puma Biotechnology Reports Second Quarter 2017 Financial Results
  14. PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Puma Biotechnology, Inc. - PBYI
  15. Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings?
  16. Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP)
  17. What's in Store for Puma (PBYI) this Earnings Season?
  18. Today's Research Reports on Trending Tickers: CombiMatrix Corporation and Puma Biotechnology
  19. Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States

SEC Filings

  1. 8-K - Current report 171076645
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171074090
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171021071
  4. 8-K - Current report 171018390
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171017888
  6. 8-K - Current report 171000304
  7. S-8 - Securities to be offered to employees in employee benefit plans 17972395
  8. 8-K - Current report 17970475
  9. 8-K - Current report 17911543
  10. 8-K - Current report 17891273